Research Topics
| Arlene A ForastiereSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology GroupMichael K Gibson
Department of Medical Oncology, Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
J Clin Oncol 23:3562-7. 2005....- Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology GroupHarry H Yoon
Mayo Clinic, Rochester, MN 55905, USA
BMC Cancer 11:176. 2011..As a secondary aim, we investigated the rate of allelic imbalance between germline and tumor DNA... - Chemotherapy in the treatment of locally advanced head and neck cancerArlene A Forastiere
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, Maryland 21231, USA
J Surg Oncol 97:701-7. 2008..The focus of future trials should be on survival improvement, toxicity reduction and risk stratification for treatment decision making... - Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancerArlene A Forastiere
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
N Engl J Med 349:2091-8. 2003..The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown... - Impact of surgeon and hospital volume on short-term outcomes and cost of oropharyngeal cancer surgical careChristine G Gourin
Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Laryngoscope 121:746-52. 2011..To evaluate the impact of surgeon and hospital case volume and other related variables on short-term outcomes after surgery for oropharyngeal cancer... - Impact of surgeon and hospital volume on short-term outcomes and cost of laryngeal cancer surgical careChristine G Gourin
Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Laryngoscope 121:85-90. 2011..To evaluate the impact of surgeon and hospital case volume and other related variables on short-term outcomes after surgery for laryngeal cancer... - Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancerLawrence Kleinberg
Sidney Kimmel Oncology Center at Johns Hopkins, Baltimore, MD 21231, USA
Int J Radiat Oncol Biol Phys 56:328-34. 2003..To assess the long-term survival results after cisplatin, protracted infusion 5-fluorouracil, and concurrent radiotherapy (RT) followed by surgical resection of esophageal cancer... - Volume-based trends in surgical care of patients with oropharyngeal cancerChristine G Gourin
Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Laryngoscope 121:738-45. 2011..Positive volume-outcome relationships exist for diseases treated with technically complex surgery. Contemporary patterns of oropharyngeal cancer surgery by hospital and surgeon volume are poorly defined... - Combined-modality therapy for esophageal cancer: are we making progress?Michael K Gibson
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Cancer J 9:238-40. 2003 - Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?Robert A Meguid
Division of Thoracic Surgery, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
J Thorac Cardiovasc Surg 138:1309-17. 2009..We hypothesized that most relapses in patients with esophageal cancer having neoadjuvant chemoradiation therapy would occur outside of the surgical and radiation fields... - HPV-associated head and neck cancer: a virus-related cancer epidemicShanthi Marur
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Lancet Oncol 11:781-9. 2010.... - Neck dissection followed by radiotherapy or chemoradiotherapy for small primary oropharynx carcinoma with cervical metastasisAshok N Reddy
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Laryngoscope 115:1196-200. 2005..75%. CONCLUSION: Initial neck dissection followed by primary radiation therapy to the primary site and neck with or without chemotherapy is an effective therapy for small primary oropharynx cancers with N2 or greater cervical metastases... - Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancerShanthi Marur
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
Curr Opin Oncol 22:206-11. 2010..This review will discuss some of the novel approaches to treating head and neck squamous cell cancer, particularly the introduction of biological agents into treatment paradigms, and some of the challenges arising as the field advances... - Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology GroupMary Armanios
Johns Hopkins University, Baltimore, MD 21205, USA
J Clin Oncol 22:4495-9. 2004..To evaluate the effect of postoperative paclitaxel and cisplatin on 2-year survival in patients with completely resected adenocarcinoma of the distal esophagus, gastro-esophageal (GE) junction, and cardia... - Multidisciplinary approaches in the management of advanced head and neck tumors: state of the artMichael K Gibson
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, Maryland 21231, USA
Curr Opin Oncol 16:220-4. 2004..This review presents selected advances in primary research in head and neck cancer during the year 2003... - Head and neck cancer: changing epidemiology, diagnosis, and treatmentShanthi Marur
Bunting Blaustein CRB1 G92, 1650 Orleans St, Baltimore, MD 21231 1000, USA smarur1 jhmi edu
Mayo Clin Proc 83:489-501. 2008.... - Reassessment of the role of induction chemotherapy for head and neck cancerMichael K Gibson
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
Lancet Oncol 7:565-74. 2006..In this review we summarise data for the use of induction chemotherapy to define better which patients will likely benefit from this approach now and which questions are important in the design of future clinical trials... - Chemoradiation in the management of esophageal cancerLawrence Kleinberg
Department of Radiation Oncology and Molecular Sciences, Division of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231 2410, USA
J Clin Oncol 25:4110-7. 2007.... - Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagusElisabeth I Heath
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Invest New Drugs 20:95-9. 2002..The objective of this trial was to determine the complete and partial response rate of docetaxel in patients with incurable adenocarcinoma of the esophagus... - Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implicationsEric L Powell
Department of Pathology, Johns Hopkins University, Baltimore, MD, USA
Am J Surg Pathol 29:1497-504. 2005..This loss of MTAP during 9p21 homozygous deletion might be exploited therapeutically using de novo purine synthesis antimetabolites to treat a subset of invasive gastroesophageal adenocarcinomas and esophageal precursor lesions... - Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcomeHarry H Yoon
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, CRB2 5M 41, Baltimore, MD 21231, USA
Future Oncol 4:413-25. 2008..We attempt to clarify the somewhat unwieldy body of literature in this area, with a focus on adenocarcinoma, keeping the clinician and clinical researcher particularly in mind... - Volume-based trends in thyroid surgeryChristine G Gourin
Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins University, 601 N Caroline St, Ste 6260, Baltimore, MD 21287, USA
Arch Otolaryngol Head Neck Surg 136:1191-8. 2010..to characterize contemporary patterns of thyroid surgical care and variables associated with access to high-volume care... - Head and neck cancer: recent advances and new standards of careArlene A Forastiere
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Clin Oncol 24:2603-5. 2006 - Volume-based trends in laryngeal cancer surgeryChristine G Gourin
Department of Otolaryngology Head and Neck Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Laryngoscope 121:77-84. 2011..Positive volume-outcome relationships exist for diseases treated with technically complex surgery. Contemporary patterns of laryngeal cancer surgery by hospital and surgeon volume are poorly defined... - Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinomaMalcolm V Brock
Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Clin Cancer Res 9:2912-9. 2003..The association of clinicopathological and biomolecular risk factors to survival and recurrence was performed using the Log-rank test and Cox proportional hazards model for multivariate analysis... - Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapyJohn R Doty
Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Ann Thorac Surg 74:227-31; discussion 231. 2002..Squamous cell carcinoma patients are nearly twice as likely to develop postoperative complications and are more likely to have respiratory complications than adenocarcinoma patients... - Organ preservation trials for laryngeal cancerJill Gilbert
Louisiana State University, Health Sciences Center Stanley, C. Scott Cancer Center, 433 Bolivar Street, New Orleans, LA 70112, USA
Otolaryngol Clin North Am 35:1035-54, vi. 2002.... - Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399Anthony J Cmelak
Vanderbilt University Medical Center, Nashville, TN 37232 5671, USA
J Clin Oncol 25:3971-7. 2007..This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable stage III/IVA and IVB larynx and oropharynx (OP) cancer patients... - Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questionsArlene A Forastiere
J Clin Oncol 25:2152-5. 2007 - Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitizationLawrence Kleinberg
Johns Hopkins University, MD, USA
Nat Clin Pract Oncol 4:282-94. 2007..The recent clinical development of biologic, targeted therapies provides a new avenue for the study of chemoradiotherapy and an opportunity to increase long-term survival... - Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neckBonnie S Glisson
University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 20:1593-9. 2002..To assess the antitumor activity and toxicity of docetaxel plus cisplatin chemotherapy in patients with recurrent or incurable squamous cell carcinoma of the head and neck (SCCHN)... - An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancerDavid J Adelstein
Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Ohio 44195, USA
J Clin Oncol 21:92-8. 2003..The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer... - Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapyAthanassios Argiris
Feinberg School of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
J Clin Oncol 22:262-8. 2004..To evaluate the outcome of elderly patients with head and neck cancer undergoing palliative chemotherapy... - Organ preservation for cancer of the larynx: current indications and future directionsJill Gilbert
Louisiana State University Health Sciences Center, Stanley S Scott Cancer Center, New Orleans, LA, USA
Semin Radiat Oncol 14:167-77. 2004..It remains to be seen whether such interventions can improve on the excellent locoregional control shown in the landmark Intergroup trial... - Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neckJay S Cooper
New York University Medical Center, New York, USA
N Engl J Med 350:1937-44. 2004..However, the combined treatment is associated with a substantial increase in adverse effects... - Is there a new role for induction chemotherapy in the treatment of head and neck cancer?Arlene A Forastiere
J Natl Cancer Inst 96:1647-9. 2004 - Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology GroupCorey J Langer
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer Invest 22:823-31. 2004..Protracted exposure to paclitaxel may overcome resistance observed by using shorter infusions. Therefore we sought to evaluate paclitaxel by 96-hour infusion in both treatment-naïve and previously treated patients with SCCHN... - Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyBarbara Burtness
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
J Clin Oncol 23:8646-54. 2005..These cancers are rich in epidermal growth factor receptor (EGFR). We wished to determine whether the addition of cetuximab, which inhibits activation of EGFR, would improve PFS... - Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology GroupJill Gilbert
Louisiana State University Medical Center, New Orleans, Louisiana, USA
Head Neck 28:197-204. 2006..The poor response rate in adenoid cystic carcinoma is consistent with prior reports in this chemoresistant histologic subtype... - Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinomaElisabeth I Heath
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
Invest New Drugs 24:135-40. 2006..The objectives of the trial were to determine pathologic complete response rate (pCR), overall response rate, progression-free survival, pattern of disease relapse, and two-year and overall survival... - American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancerDavid G Pfister
American Society of Clinical Oncology, Alexandria, VA, VA 22314, USA
J Clin Oncol 24:3693-704. 2006.... - Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancerDong M Shin
Department of Thoracic/Head and Neck Medical Oncology, Diagnostic Imaging, Biostatistics, Head and Neck Surgery, and Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
J Clin Oncol 20:364-70. 2002..Combined 13cRA, IFNalpha, and cisplatin was clinically active in extensive locally advanced disease. Each agent had independent, non-cross-resistant biologic effects in vitro, which may account for the combination's clinical activity... - Head and neck cancersArlene A Forastiere
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
J Natl Compr Canc Netw 3:316-91. 2005 - Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyEzra E W Cohen
Section of Hematology Oncology, Department of Medicine, University of Chicago Division of Biological Sciences, 5801 S Ellis, Chicago, IL 60637, USA
J Clin Oncol 26:4708-13. 2008..This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer... - Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trialElisabeth I Heath
Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
J Natl Cancer Inst 99:545-57. 2007....
Research Grants
- EASTERN COOPERATIVE ONCOLOGY GROUPArlene Forastiere; Fiscal Year: 2007..Our accrual and committee involvement is expected to continue to grow because of expanding clinical programs and faculty made possible with a new Cancer Center facility and research buildings occupied since late 2000. ..